UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 147

Sortiert nach

Economic burden of stroke: a systematic review on post-stroke care

The European journal of health economics, 2019-02, Vol.20 (1), p.107-134

2019

Volltextzugriff (PDF)

Evaluation of undetected cases during the COVID-19 epidemic in Austria

BMC infectious diseases, 2021-01, Vol.21 (1), p.70-70, Article 70

2021

Volltextzugriff (PDF)

Cost-effectiveness of primary HPV screening for cervical cancer in Germany – a decision analysis

European journal of cancer (1990), 2011-07, Vol.47 (11), p.1633-1646

2011

Volltextzugriff (PDF)

Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C

Journal of viral hepatitis, 2010-01, Vol.17 (1), p.34-50

2010

Volltextzugriff (PDF)

PMD80 - IS SCREENING FOR OVARIAN CANCER EFFECTIVE AND COST EFFECTIVE IN AUSTRIA? A MODEL-BASED ECONOMIC EVALUATION

Value in health, 2018-10, Vol.21, p.S256-S257

2018

Volltextzugriff (PDF)

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

Gut, 2003-03, Vol.52 (3), p.425-432

2003

Volltextzugriff (PDF)

Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria

SpringerPlus, 2015-12, Vol.4 (1), p.752-752, Article 752

2015

Volltextzugriff (PDF)

The Benefit-Harm Frontier of Different Primary Screening Strategies for Cervical Cancer in Germany

Value in health, 2013-11, Vol.16 (7), p.A574-A575

2013

Volltextzugriff (PDF)

PCN43 NEW CERVICAL CANCER SCREENING POLICY IN GERMANY - WHAT IS THE IMPACT ON THE BENEFIT-HARM BALANCE?

Value in health, 2019-11, Vol.22, p.S443-S443

2019

Volltextzugriff (PDF)

The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening

Value in health, 2014-11, Vol.17 (7), p.A559-A559

2014

Volltextzugriff (PDF)

Epigenome-based cancer risk prediction: rationale, opportunities and challenges

Nature reviews. Clinical oncology, 2018-05, Vol.15 (5), p.292-309

2018

Volltextzugriff (PDF)

Uncertainty and Cost-Effectiveness Analysis of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

Value in health, 2013-11, Vol.16 (7), p.A409-A409

2013

Volltextzugriff (PDF)

Framework for Evidence Assessment Based on Grade and Application to HPV Vaccination in Males in the European Health Care Context

Value in health, 2013-11, Vol.16 (7), p.A327-A327

2013

Volltextzugriff (PDF)

EE406 Colorectal Cancer Screening - Benefit-Harm and Cost-Effectiveness Analysis of Population-Wide Screening Strategies in Austria

Value in health, 2022-12, Vol.25 (12), p.S135-S135

2022

Volltextzugriff (PDF)

PCN4 Decision-Analytic Model for the First-Line Therapy of Chronic Myeloid Leukemia

Value in health, 2012-11, Vol.15 (7), p.A409-A409

2012

Volltextzugriff (PDF)

PRM22 Microsimulation Methods Used for Health Policy Decisions in Personalized Medicine Under Constrained Resources

Value in health, 2011, Vol.14 (7), p.A424-A425

2011

Volltextzugriff (PDF)

Gesundheitsökonomische Aspekte chronischer Infektionskrankheiten am Beispiel der chronischen Hepatitis C

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2006-01, Vol.49 (1), p.57-63

2006

Volltextzugriff (PDF)

CO4 How Can the Long-Term Benefits and Harms of Screening Be Transparently Quantified and Contrasted for Informed Decision-Making? Colorectal Cancer Screening for Persons at Familial Risk (FARKOR)

Value in health, 2022-12, Vol.25 (12), p.S17-S17

2022

Volltextzugriff (PDF)

HPR171 COVID 19 Vaccination - How to Support Decisions on Vaccination Prioritization for New Variants of Concern?

Value in health, 2022-12, Vol.25 (12), p.S263-S263

2022

Volltextzugriff (PDF)

HTA170 Including Decision-Analytic Benefit-Harm Evaluation in HTA - Different Age Ranges and Screening Intervals in Breast Cancer Screening in Germany

Value in health, 2022-12, Vol.25 (12), p.S329-S329

2022

Volltextzugriff (PDF)

Prevention of breast&ovarian cancer in women with BRCA-1/2 mutations - A decision-analytic evaluation

European journal of public health, 2021-10, Vol.31 (Supplement_3)

2021

Volltextzugriff (PDF)

P16 COVID-19 Vaccination Strategies Considering a Vaccine Adapted to a New Variant of Concern: A Decision-Analytic Modeling Study

Value in health, 2022-07, Vol.25 (7), p.S290-S290

2022

Volltextzugriff (PDF)

Fractional flow reserve for the prediction of cardiac events after coronary stent implantation: results of a multivariate analysis

Heart (British Cardiac Society), 2005-02, Vol.91 (2), p.203-206

2005

Volltextzugriff (PDF)

POSA172 How to Optimize COVID-19 Vaccination Considering Limited Vaccination Capacities: A Decision-Analytic Framework and Modeling Study

Value in health, 2022-01, Vol.25 (1), p.S121-S121

2022

Volltextzugriff (PDF)

1 – 25 von 147

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(109)

Publikationsform

Artikel
(146)
Tagungsberichte
(1)

Sprache

Englisch
(115)
Polnisch
(28)
Deutsch
(4)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Economic burden of stroke: a systematic review on post-stroke care

Evaluation of undetected cases during the COVID-19 epidemic in Austria

Cost-effectiveness of primary HPV screening for cervical cancer in Germany – a decision analysis

Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C

Personalized early detection and prevention of breast cancer: ENVISION consensus statement

PMD80 - IS SCREENING FOR OVARIAN CANCER EFFECTIVE AND COST EFFECTIVE IN AUSTRIA? A MODEL-BASED ECONOMIC EVALUATION

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria

The Benefit-Harm Frontier of Different Primary Screening Strategies for Cervical Cancer in Germany

PCN43 NEW CERVICAL CANCER SCREENING POLICY IN GERMANY - WHAT IS THE IMPACT ON THE BENEFIT-HARM BALANCE?

The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening

Epigenome-based cancer risk prediction: rationale, opportunities and challenges

Uncertainty and Cost-Effectiveness Analysis of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

Framework for Evidence Assessment Based on Grade and Application to HPV Vaccination in Males in the European Health Care Context

EE406 Colorectal Cancer Screening - Benefit-Harm and Cost-Effectiveness Analysis of Population-Wide Screening Strategies in Austria

PCN4 Decision-Analytic Model for the First-Line Therapy of Chronic Myeloid Leukemia

PRM22 Microsimulation Methods Used for Health Policy Decisions in Personalized Medicine Under Constrained Resources

Gesundheitsökonomische Aspekte chronischer Infektionskrankheiten am Beispiel der chronischen Hepatitis C

CO4 How Can the Long-Term Benefits and Harms of Screening Be Transparently Quantified and Contrasted for Informed Decision-Making? Colorectal Cancer Screening for Persons at Familial Risk (FARKOR)

HPR171 COVID 19 Vaccination - How to Support Decisions on Vaccination Prioritization for New Variants of Concern?

HTA170 Including Decision-Analytic Benefit-Harm Evaluation in HTA - Different Age Ranges and Screening Intervals in Breast Cancer Screening in Germany

Prevention of breast&ovarian cancer in women with BRCA-1/2 mutations - A decision-analytic evaluation

P16 COVID-19 Vaccination Strategies Considering a Vaccine Adapted to a New Variant of Concern: A Decision-Analytic Modeling Study

Fractional flow reserve for the prediction of cardiac events after coronary stent implantation: results of a multivariate analysis

POSA172 How to Optimize COVID-19 Vaccination Considering Limited Vaccination Capacities: A Decision-Analytic Framework and Modeling Study

Suchergebnisse filtern